iBio, Inc.

IBIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $56.4M $8.6M $14.2M $4.3M $22.7M $77.4M $55.1M $4.4M
Accounts Receivable — — $0 $0 $1.0M $426.0K $75.0K $97.0K
Inventory — — $0 $0 $3.9M $27.0K — —
Total Current Assets $92.2M $9.7M $15.7M $26.3M $45.1M $104.6M $61.7M $4.8M
Property, Plant & Equipment $3.1M $3.2M $3.6M $4.2M $1.4M $8.6M $3.7M $24.4M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) $1.8M $6.8M $5.4M $5.4M $4.9M $952.0K $1.1M $1.4M
Total Assets $99.1M $23.2M $28.7M $41.2M $99.4M $147.0M $94.2M $30.6M
Liabilities
Accounts Payable $4.4M $2.2M $358.0K $1.8M $4.3M $2.3M $1.8M $1.0M
Total Current Liabilities $11.7M $6.1M $3.8M $22.1M $30.4M $6.6M $5.2M $3.5M
Long-Term Debt — — — — — — — —
Total Liabilities $13.4M $8.3M $7.4M $25.8M $35.9M $38.4M $37.6M $28.1M
Stockholders' Equity
Retained Earnings $-365.3M $-332.2M $-313.8M $-288.9M $-223.9M $-173.6M $-150.4M $-105.8M
Total Stockholders' Equity $85.7M $14.9M $21.3M $15.4M $63.5M $108.6M $56.6M $2.5M
← Newer Page 1 of 2 Older →